Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: A prospective multicenter evaluation

Pediatric Infectious Disease Journal

Volumn 29, Issue 9, 2010, Pages 816-821

  Villarroel, Milena ^a,b   Avilés, Carmen L ^b,c   Silva, Pamela ^b,c   Guzmán, Ana M ^d   Poggi, Helena ^d   Alvarez, Ana M ^b,e   Becker, Ana ^b,f   O'Ryan, Miguel ^g   Salgado, Carmen ^h   Topelberg, Santiago ^b,i   Tordecilla, Juan ^b,i   Varas, Mónica ^a,e   Viviani, Tamara ^a,f   Zubieta, Marcela ^h   Santolaya, María E ^a,b  

^a HOSPITAL LUIS CALVO MACKENNA   (Chile)

^b Subcommittee of Infectious Diseases   (Chile)

^c HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e HOSPITAL SAN JUAN DE DIOS   (Chile)

^f HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^g UNIVERSITY OF CHILE   (Chile)

^h Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

ⁱ HOSPITAL ROBERTO DEL RÍO   (Chile)

Author keywords

febrile neutropenia; invasive fungal disease; risk factors

Indexed keywords

ANTIFUNGAL AGENT; C REACTIVE PROTEIN; GALACTOMANNAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CHILE; CLINICAL FEATURE; CLINICAL TRIAL; EPIDEMIC; FEBRILE NEUTROPENIA; FEMALE; FEVER; FUNGUS CULTURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTICENTER STUDY; MYCOSIS; NEUTROPHIL COUNT; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 77955984917     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181e7db7f     Document Type: Article

References (40)

1. Steinbach WJ, Walsh TT. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663-678.
2. Dornbusch H, Manzini P, Roilides E, et al. Invasive fungal infections in children. Pediatr Infect Dis J. 2009;28:734-737.
3. Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter study. Pediatr Infect Dis J. 2006; 25:634-639.
4. Pappas P, Kauffman C, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
5. Segal B. Aspergillosis. N Engl J Med. 2009;360:1870-1884.
6. Blyth C, Chen S, Slavin M, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;123:1360-1368.
7. Moran C, Grussemeyer CA, Spalding JR, et al. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J. 2009;28:433-435.
8. Steinbach W. Pediatric aspergillosis disease and treatment differences in children. Pediatr Infect Dis J. 2005;24:358-364.
9. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis. Pediatrics. 2008;121:1286-1294.
10. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242-1250.
11. Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal disease in neutropenic patients. Curr Opin Infect Dis. 2009;22:385-393.
12. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am. 2006;20:711-727.
13. Thomas KE. The radiological spectrum of invasive aspergillosis in children. Pediatr Radiol. 2003;33:453-460.
14. Maertens J, Theunissen K, Verhoef G, et al. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis. 2004;39:289-290.
15. Pffeifer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006. 2006;42: 1417-1427.
16. Verweij PE, Mennink-Kersten MA. Issues with galactomannan testing. Med Mycol. 2006;44:179-183.
17. Jordanides NE, Allan EK, Mclintock LA, et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplant. 2005;35:389-395.
18. El-Mahallawy HA, Shaker HH, Helmy HA, et al. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatrics cancer patients. Med Mycol. 2006;44:733-739.
19. Donelly JP. Polymerase chain reaction for diagnosis invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42:487-489.
20. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;15:730-751.
21. Klastersky J. Antifungal therapy in patients with fever and neutropenia\more rational and less empirical? N Engl J Med. 2004;351:1445-1447.
22. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110:273-284.
23. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hema-tological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103-1110.
24. Kobayashi R, Kaneda M, Sato T, et al. The clinical feature of invasive fungal infection in pediatric patients with haematologic and malignant diseases: a 10-years analysis at a single institution in Japan. J Pediatr Hematol Oncol. 2008;30:886-890.
25. Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazol prophylaxis. Pediatr Blood Cancer. 2009;52:470-475.
26. Lucero Y, Brucher R, Alvarez AM, et al. Infección micótica profunda en niños con cáncer, neutropenia y fiebre. Rev Med Chile. 2002;130:1139-1146.
27. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia and fever. J Clin Oncol. 2001;19:3415-3421.
28. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever and neutropenia. Clin Infect Dis. 2002;35:678-683.
29. De Pauw B, Walsh T, Donnelly P, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORT/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
30. Santolaya ME, Rabagliatti R, Bidart T, et al. Consenso nacional: manejo racional del paciente con neutropenia y fiebre. Rev Chil Infectol. 2005;22: S79-S113.
31. Pinel C, Fricker-Hidalgo H, Lebeau B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol. 2003;41:2184-2186.
32. Goldstein B, Giroir A, Randolph A; International consensus conference on pediatric sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2-8.
33. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-379.
34. Hope WW, Walsh T, Denning D. Laboratory diagnosis of invasive aspergil-losis. Lancet Infect Dis. 2005;5:609-622.
35. Odabasi Z, Mattiuzzi G, Estey E, et al. ß-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukaemia and myelodisplatic syndrome. Clin Infect Dis. 2004;39:199-205.
36. Portugal R, Garnica M, Nucci M. Index to predict invasive mold infection in high risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27:3849-3854.
37. Maaroufi Y, Heymans C, De Bruyne JM, et al. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-Based PCR assay. J Clin Microbiol. 2003;41:3293-3298.
38. Marr KA, Balajee A, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive as-pergillosis: variables that affect performance. J Infect Dis. 2004;190:641-649.
39. Mclintock LA, Jones BL. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol. 2004;126:289-297.
40. Buchheidt D, Baust C, Skladny H, et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis. 2001;33:428-435.